MNKD Insider Trading
Insider Ownership Percentage: 3.00%
Insider Buying (Last 12 Months): $0.00
Insider Selling (Last 12 Months): $2,696,774.66
MannKind Share Price & Price History
Current Price: $5.97
Price Change: ▼ Price Decrease of -0.14 (-2.29%)
As of 01/30/2025 05:00 PM ET
MannKind Insider Trading History
MannKind Institutional Trading History
Data available starting January 2016
MannKind Corporation, a biopharmaceutical company, focuses on the development and commercialization of inhaled therapeutic products for endocrine and orphan lung diseases in the United States. It offers Afrezza, an inhaled insulin used to improve glycemic control in adults with diabetes, and the V-Go wearable insulin delivery device, which provides continuous subcutaneous infusion of insulin in adults. The company's product pipeline also includes Tyvaso DPI (Treprostinil), an inhalation powder for the treatment of pulmonary arterial hypertension and pulmonary hypertension associated with interstitial lung disease; MNKD-101, a nebulized formulation of clofazimine, for the treatment of severe chronic and recurrent pulmonary infections, including nontuberculous mycobacterial lung disease; MNKD-201, a dry-powder formulation of nintedanib, for the treatment of idiopathic pulmonary fibrosis (IPF). In addition, it has collaboration and license agreement with United Therapeutics Corporation for development, regulatory, and commercial activities of Tyvaso DPI; co-promotion agreement with Vertice Pharma to promote Thyquidity; and collaboration agreement with Thirona to evaluate the therapeutic for the treatment of pulmonary fibrosis. Further, the company has supply and distribution agreement with Biomm S.A. for the commercialization of Afrezza in Brazil; and license and distribution agreement with Cipla Ltd. for the marketing and distribution of Afrezza in India. MannKind Corporation was incorporated in 1991 and is headquartered in Danbury, Connecticut.
Read More on MannKind
Volume
1,693,949 shs
Average Volume
1,941,639 shs
Market Capitalization
$1.65 billion
P/E Ratio
85.29
Dividend Yield
N/A
Beta
1.29
Who are the company insiders with the largest holdings of MannKind?
Who are the major institutional investors of MannKind?
MannKind's top institutional shareholders include:
- TSP Capital Management Group LLC — 0.91%
- 180 Wealth Advisors LLC — 0.76%
- Hennion & Walsh Asset Management Inc. — 0.09%
- Calamos Advisors LLC — 0.07%
- China Universal Asset Management Co. Ltd. — 0.02%
- New Wave Wealth Advisors LLC — 0.02%
Learn More about top institutional investors of MannKind stock.
Which institutional investors are selling MannKind stock?
During the last quarter, MNKD stock was sold by these institutional investors:
- Calamos Advisors LLC
- International Assets Investment Management LLC
- SG Americas Securities LLC
- Wealth Enhancement Advisory Services LLC
- Hennion & Walsh Asset Management Inc.
Within the last year, company insiders that have sold MannKind company stock include:
- Michael Castagna (CEO)
- Steven B Binder (EVP)
- Steven B Binder (Director)
- Stuart A Tross (Insider)
- David Thomson (EVP)
Learn More investors selling MannKind stock.
Which institutional investors are buying MannKind stock?
During the previous quarter, MNKD stock was bought by institutional investors including:
- New Wave Wealth Advisors LLC
- 180 Wealth Advisors LLC
- TSP Capital Management Group LLC
- China Universal Asset Management Co. Ltd.